BACKGROUND Peroxisome proliferator-activated receptor-g (PPAR-g) exhibits anti-inflammatory and anti-diabetic properties, and is protective against cardiovascular diseases. This study aimed to determine the effects of a PPAR-g agonist pioglitazone on atherogenesis in an ApoE knockout mouse (ApoE-/-) diabetic mouse model and in a cultured vascular smooth muscle cells (VSMCs) model. MATERIAL AND ...

BACKGROUND & AIMS Nonalcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease for which there is limited therapy available. Insulin sensitizing, anti-inflammatory, and antifibrotic properties of thiazolidinediones support their use in treating NASH. We have evaluated pioglitazone in the treatment of nondiabetic patients with NASH. METHODS We randomized 74 nondiabetic patie...

OBJECTIVE To determine whether changes in standard and novel risk factors during the Actos Now for Prevention of Diabetes trial explained the slower rate of carotid intima media thickness (CIMT) progression with pioglitazone treatment in persons with prediabetes. METHODS AND RESULTS CIMT was measured in 382 participants at the beginning and up to 3 additional times during follow-up of the Act...

Otsuka Long Evans Tokushima Fatty (OLETF) rats were developed as a model of non-insulin-dependent diabetes mellitus (NIDDM) with mild obesity. We reported that the daily profiles of energy expenditure associated with two peaks (one between 05:00 and 08:00 and the other between 20:00 and 22:00) were observed at 8 weeks of age (without NIDDM), while these two peaks disappeared at 24 weeks of age ...

OBJECTIVE To compare the efficacy and safety of generic (Utmos) and original (Actos) 30 mg Pioglitazone tablets. STUDY DESIGN A multicenter, parallel randomized, double-blinded, controlled study. MATERIAL AND METHOD Type 2 diabetic patients, with glycosylated hemoglobin (HbA,) > or = 7.0%, who received Metformin not less than 1000 mg/day over three months were recruited. Patients were rando...

BACKGROUND Patients with cardiovascular risk factors have endothelial dysfunction, a key element in the pathogenesis of atherosclerosis. The thiazolidinediones have been shown to exert multiple antiatherosclerotic actions in diabetic patients. This study tested the hypothesis that pioglitazone improves endothelial function in nondiabetic patients with major risk factors. METHODS AND RESULTS T...

Pioglitazone and other thiazolidinediones (TZDs) initially showed great promise as unique receptor-mediated oral therapy for type 2 diabetes, but a host of serious side effects, primarily cardiovascular, have limited their utility. It is crucial at this point to perform a risk- benefit analysis to determine what role pioglitazone should play in our current treatment of type 2 diabetes and where...

Introduction: Non-alcoholic fatty liver is one of the most prevalent digestive diseases in the world and its prevalence is increasing rapidly. The objective of this study was to compare the treatment effect of pioglitazone and metformin on fatty liver. Materials and methods: This double blinded clinical trial study was performed in 2012 among patients referring to gastrointestinal clinic...

HYPOTHESIS Palmitate causes insulin resistance (IR) in insulin target tissue. Pioglitazone (an anti-hyperglycemic agent) and epigallocatechin gallate (EGCG, a dietary supplement) can be used for the treatment of type 2 diabetes. However, their molecular effects on gluconeogenesis remain unclear. OBJECTIVE Hence, we aimed to investigate the simultaneous effect of these anti-hyperglycemic agent...

BACKGROUND/AIMS Pioglitazone, a peroxisome proliferator-activated receptor γ activator, is clinically used to treat insulin resistance. However, the underlying mechanism of pioglitazone's action remains unclear. We investigated whether, and how, pioglitazone modulates serum level of retinol binding protein 4 (RBP4), an adipocytokine associated with obesity and insulin resistance. METHODS Insu...